Press Releases

Date Title and Summary View
Toggle Summary MediWound Reports Second Quarter 2022 Financial Results and Provides Company Updates
Positive Results in Two Phase 2 Trial s of EscharEx FDA Assigned PDUFA Target Date of January 1 ,   202 3   for NexoBrid BLA Enhance d the Board and L eadership T eam Conference C all B egins T oday at 8:30 AM   Eastern Time YAVNE, Israel , Aug. 09, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd.
View HTML
Toggle Summary MediWound Enhances Its Board and Executive Leadership Team
Mr. N achum Shamir appointed as Chairman   of the Board Dr. Robert Snyder   appointed as   Chief Medical Officer YAVNE, Israel , Aug. 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic
View HTML
Toggle Summary MediWound Announces U.S. FDA Acceptance of Biologics License Application for NexoBrid for the Treatment of Severe Thermal Burns
Prescription Drug User Fee Act (PDUFA) target date of January 1, 2023 YAVNE, Israel , Aug. 03, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (“MediWound”), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration,
View HTML
Toggle Summary MediWound Schedules Second Quarter 2022 Financial Results
Conference Call and Webcast Scheduled for Tuesday, August 9, 2022 at 8:30 AM ET Call Scheduled for Tuesday, August 9, 2022 at 8:30 AM Eastern Time YAVNE, Israel , Aug. 01, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully integrated biopharmaceutical company focused on next-generation
View HTML
Toggle Summary MediWound Announces Positive Initial Data from its U.S. Phase I/II Study of MW005 for the Treatment of Basal Cell Carcinoma
MW005 Shown to Be Safe and Well-Tolerated Target Lesions Clearance Data Provides Clinical Efficacy Proof-of-Concept YAVNE, Israel , July 11, 2022 (GLOBE NEWSWIRE) --  MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company focused on next-generation
View HTML
Toggle Summary MediWound Announces Presentation on EscharEx at the Advanced Wound Care Summit in Boston on July 13
YAVNE, Israel , July 08, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration, today announced an oral presentation at the Advanced Wound Care Summit taking place
View HTML
Toggle Summary MediWound Announces Positive Results from its U.S. Phase 2 Pharmacology Study of EscharEx for Debridement of Lower Leg Ulcers
EscharEx Showed   Safe, Effective and Rapid Debridement in VLUs and DFUs Data Demonstrate s EscharEx Reduce d   Wound Size, Biofilm and Bacterial Burden YAVNE, Israel , July 07, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD) (the “Company”), a fully-integrated biopharmaceutical company
View HTML
Toggle Summary MediWound to Host a Key Opinion Leader Investor Day on EscharEx
In-Person KOL Breakfast Meeting to be held on Tuesday, July 12th in New York City YAVNE, Israel , July 05, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration,
View HTML
Toggle Summary MediWound Names Mr. Tzvi Palash as Chief Operating Officer
Brings Extensive Operational Experience from International Pharmaceutical Companies YAVNE, Israel , June 30, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a fully-integrated biopharmaceutical company focused on next-generation biotherapeutic solutions for tissue repair and regeneration,
View HTML
Toggle Summary MediWound Announces CEO Transition
Ofer Gonen , current Board member and CEO of Clal Biotechnology Industries Ltd., appointed as New CEO – Effective June 30 Will replace current CEO Sharon Malka , who will join the Board of Directors YAVNE, Israel , May 17, 2022 (GLOBE NEWSWIRE) -- MediWound Ltd.
View HTML